Open Access
Open access
Nature Communications, volume 10, issue 1, publication number 524

The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model

Liu Yang 1, 2
Gao Yamin 2, 3
Liu Jianxiong 4
Tan Yaoju 4
Liu Zhiyong 2
Chhotaray Chiranjibi 2, 3
Jiang Huofeng 2, 5
Lu Zhili 2
Gift Chiwala 2, 3
Wang Shuai 2, 3
Makafe Gaelle 2, 3
Islam Md Mahmudul 2, 3
Hameed H M Adnan 2, 3
Cai Xingshan 4
Wang Changwei 2
Li Xinjie 4
Tan Shouyong 4
2
 
State Key Laboratory of Respiratory Disease, Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou, China
4
 
State Key Laboratory of Respiratory Disease, Department of Clinical Laboratory, Guangzhou Chest Hospital, Guangzhou, China
5
 
School of life Sciences, University of Science and Technology of China, Hefei, China
Publication typeJournal Article
Publication date2019-01-31
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor16.6
ISSN20411723
General Chemistry
General Biochemistry, Genetics and Molecular Biology
General Physics and Astronomy
Abstract
Buruli ulcer (BU) is an emerging infectious disease that causes disfiguring skin ulcers. The causative agent, Mycobacterium ulcerans, secretes toxin called mycolactone that triggers inflammation and immunopathology. Existing treatments are lengthy and consist of drugs developed for tuberculosis. Here, we report that a pyrazolo[1,5-a]pyridine-3-carboxamide, TB47, is highly bactericidal against M. ulcerans both in vitro and in vivo. In the validated mouse model of BU, TB47 alone reduces M. ulcerans burden in mouse footpads by more than 2.5 log10 CFU compared to the standard BU treatment regimen recommended by the WHO. We show that mutations of ubiquinol-cytochrome C reductase cytochrome subunit B confer resistance to TB47 and the dissimilarity of CydABs from different mycobacteria may account for their differences in susceptibility to TB47. TB47 is highly potent against M. ulcerans and possesses desirable pharmacological attributes and low toxicity that warrant further assessment of this agent for treatment of BU.Combination therapy for Buruli ulcer (BU) is suboptimal. Here, Liu et al. show that the candidate drug TB47 has potent bactericidal activity against Mycobacterium ulcerans in vitro and in a mouse model, which underscores its potential for shortening the course of BU and treating other mycobacterial diseases.

Citations by journals

1
2
3
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry, 3, 7.32%
Journal of Medicinal Chemistry
3 publications, 7.32%
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, 3, 7.32%
Antimicrobial Agents and Chemotherapy
3 publications, 7.32%
Pharmaceuticals
Pharmaceuticals, 2, 4.88%
Pharmaceuticals
2 publications, 4.88%
Progress in Biophysics and Molecular Biology
Progress in Biophysics and Molecular Biology, 2, 4.88%
Progress in Biophysics and Molecular Biology
2 publications, 4.88%
Biosensors and Bioelectronics
Biosensors and Bioelectronics, 2, 4.88%
Biosensors and Bioelectronics
2 publications, 4.88%
ACS Infectious Diseases
ACS Infectious Diseases, 2, 4.88%
ACS Infectious Diseases
2 publications, 4.88%
Journal of Natural Products
Journal of Natural Products, 2, 4.88%
Journal of Natural Products
2 publications, 4.88%
Frontiers in Cellular and Infection Microbiology
Frontiers in Cellular and Infection Microbiology, 1, 2.44%
Frontiers in Cellular and Infection Microbiology
1 publication, 2.44%
Frontiers in Chemistry
Frontiers in Chemistry, 1, 2.44%
Frontiers in Chemistry
1 publication, 2.44%
Journal of Infection and Public Health
Journal of Infection and Public Health, 1, 2.44%
Journal of Infection and Public Health
1 publication, 2.44%
PLoS ONE
PLoS ONE, 1, 2.44%
PLoS ONE
1 publication, 2.44%
Cell Chemical Biology
Cell Chemical Biology, 1, 2.44%
Cell Chemical Biology
1 publication, 2.44%
Biomedicine and Pharmacotherapy
Biomedicine and Pharmacotherapy, 1, 2.44%
Biomedicine and Pharmacotherapy
1 publication, 2.44%
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B, 1, 2.44%
Acta Pharmaceutica Sinica B
1 publication, 2.44%
Journal of Controlled Release
Journal of Controlled Release, 1, 2.44%
Journal of Controlled Release
1 publication, 2.44%
Immunological Reviews
Immunological Reviews, 1, 2.44%
Immunological Reviews
1 publication, 2.44%
Journal of Organic Chemistry
Journal of Organic Chemistry, 1, 2.44%
Journal of Organic Chemistry
1 publication, 2.44%
New Journal of Chemistry
New Journal of Chemistry, 1, 2.44%
New Journal of Chemistry
1 publication, 2.44%
Chemical Communications
Chemical Communications, 1, 2.44%
Chemical Communications
1 publication, 2.44%
RSC Advances
RSC Advances, 1, 2.44%
RSC Advances
1 publication, 2.44%
Expert Review of Clinical Pharmacology
Expert Review of Clinical Pharmacology, 1, 2.44%
Expert Review of Clinical Pharmacology
1 publication, 2.44%
Drug Design, Development and Therapy
Drug Design, Development and Therapy, 1, 2.44%
Drug Design, Development and Therapy
1 publication, 2.44%
Microbiology spectrum
Microbiology spectrum, 1, 2.44%
Microbiology spectrum
1 publication, 2.44%
Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America, 1, 2.44%
Proceedings of the National Academy of Sciences of the United States of America
1 publication, 2.44%
eLife
eLife, 1, 2.44%
eLife
1 publication, 2.44%
Bioorganic and Medicinal Chemistry Letters
Bioorganic and Medicinal Chemistry Letters, 1, 2.44%
Bioorganic and Medicinal Chemistry Letters
1 publication, 2.44%
European Journal of Medicinal Chemistry
European Journal of Medicinal Chemistry, 1, 2.44%
European Journal of Medicinal Chemistry
1 publication, 2.44%
Therapeutic Advances in Infectious Disease
Therapeutic Advances in Infectious Disease, 1, 2.44%
Therapeutic Advances in Infectious Disease
1 publication, 2.44%
Letters in Drug Design and Discovery
Letters in Drug Design and Discovery, 1, 2.44%
Letters in Drug Design and Discovery
1 publication, 2.44%
1
2
3

Citations by publishers

2
4
6
8
10
12
Elsevier
Elsevier, 11, 26.83%
Elsevier
11 publications, 26.83%
American Chemical Society (ACS)
American Chemical Society (ACS), 8, 19.51%
American Chemical Society (ACS)
8 publications, 19.51%
American Society for Microbiology
American Society for Microbiology, 4, 9.76%
American Society for Microbiology
4 publications, 9.76%
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 3, 7.32%
Royal Society of Chemistry (RSC)
3 publications, 7.32%
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 2, 4.88%
Multidisciplinary Digital Publishing Institute (MDPI)
2 publications, 4.88%
Frontiers Media S.A.
Frontiers Media S.A., 2, 4.88%
Frontiers Media S.A.
2 publications, 4.88%
Cold Spring Harbor Laboratory
Cold Spring Harbor Laboratory, 2, 4.88%
Cold Spring Harbor Laboratory
2 publications, 4.88%
Public Library of Science (PLoS)
Public Library of Science (PLoS), 1, 2.44%
Public Library of Science (PLoS)
1 publication, 2.44%
Wiley
Wiley, 1, 2.44%
Wiley
1 publication, 2.44%
Taylor & Francis
Taylor & Francis, 1, 2.44%
Taylor & Francis
1 publication, 2.44%
Dove Medical Press
Dove Medical Press, 1, 2.44%
Dove Medical Press
1 publication, 2.44%
Proceedings of the National Academy of Sciences (PNAS)
Proceedings of the National Academy of Sciences (PNAS), 1, 2.44%
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 2.44%
eLife Sciences Publications
eLife Sciences Publications, 1, 2.44%
eLife Sciences Publications
1 publication, 2.44%
SAGE
SAGE, 1, 2.44%
SAGE
1 publication, 2.44%
Bentham Science
Bentham Science, 1, 2.44%
Bentham Science
1 publication, 2.44%
2
4
6
8
10
12
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Liu Y. et al. The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model // Nature Communications. 2019. Vol. 10. No. 1. 524
GOST all authors (up to 50) Copy
Liu Y., Gao Y., Liu J., Tan Y., Liu Z., Chhotaray C., Jiang H., Lu Z., Gift C., Wang S., Makafe G., Islam M. M., Hameed H. M. A., Cai X., Wang C., Li X., Tan S., Zhang T. The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model // Nature Communications. 2019. Vol. 10. No. 1. 524
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1038/s41467-019-08464-y
UR - https://doi.org/10.1038%2Fs41467-019-08464-y
TI - The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model
T2 - Nature Communications
AU - Liu, Yang
AU - Gao, Yamin
AU - Liu, Jianxiong
AU - Tan, Yaoju
AU - Liu, Zhiyong
AU - Chhotaray, Chiranjibi
AU - Jiang, Huofeng
AU - Lu, Zhili
AU - Gift, Chiwala
AU - Wang, Shuai
AU - Makafe, Gaelle
AU - Islam, Md Mahmudul
AU - Hameed, H M Adnan
AU - Cai, Xingshan
AU - Wang, Changwei
AU - Li, Xinjie
AU - Tan, Shouyong
AU - Zhang, Tianyu
PY - 2019
DA - 2019/01/31 00:00:00
PB - Springer Nature
IS - 1
VL - 10
PMID - 30705268
SN - 2041-1723
ER -
BibTex
Cite this
BibTex Copy
@article{2019_Liu,
author = {Yang Liu and Yamin Gao and Jianxiong Liu and Yaoju Tan and Zhiyong Liu and Chiranjibi Chhotaray and Huofeng Jiang and Zhili Lu and Chiwala Gift and Shuai Wang and Gaelle Makafe and Md Mahmudul Islam and H M Adnan Hameed and Xingshan Cai and Changwei Wang and Xinjie Li and Shouyong Tan and Tianyu Zhang},
title = {The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model},
journal = {Nature Communications},
year = {2019},
volume = {10},
publisher = {Springer Nature},
month = {jan},
url = {https://doi.org/10.1038%2Fs41467-019-08464-y},
number = {1},
doi = {10.1038/s41467-019-08464-y}
}
Found error?